Denosumab (International Nonproprietary Name)

Denosumab is available as a solution for injection, presented in:
•A single-use vial (120 mg in 1.7 mL)
The solution is clear, colorless to yellowish, and may contain trace amounts of protein particles.
Availability may vary by country. Please consult your local label.

Subcutaneous use (injection under the skin)

This medicine is used in adults for:
• Prevention of bone complications (such as fractures or spinal cord compression) in individuals with advanced cancers that have spread to the bone.
• Treatment of giant cell tumor of bone in adults and skeletally mature adolescents when surgery is not possible or would cause severe complications.

Denosumab is a prescription medicine that helps manage bone-related conditions in certain cancer patients and individuals with giant cell tumors of bone. It is administered by injection and is typically given once every four weeks. In some cases, additional doses may be given during the first month of treatment.

This medicine works by targeting a protein called RANKL, which plays a key role in the activity of cells that break down bone. By blocking RANKL, denosumab reduces bone destruction and helps maintain bone strength. In giant cell tumors of bone, it reduces the number of harmful bone cells and promotes the formation of new bone.

Bone-modifying agent (RANKL inhibitor)

This page is intended for general informational purposes only and does not replace professional medical advice. Product availability, indications, and labeling may vary by country. Always consult your healthcare provider and refer to the locally approved product information.